National Hub meeting outcomes

c4c held the first workshop on Young Persons Advocacy Groups (YPAG) for the PPI liaisons in the National Hubs on the 28 January and 4 February held over ZOOM virtual meeting platform. In case you are not familiar with this term, A Young Persons Advisory Group (YPAG) is a group made up of children and…

IMI publishes articles about c4c progess

IMI publishes articles about the progress of c4c and closing the gap in paediatric medicine development   The Innovative Medicines Initiative (IMI) who provide grant funding for conect4children, have published an article about the important work c4c has carried out so far, to ensure that clinical trial sites across Europe are ‘trial ready’ for paediatric…

Empowering trial staff one course at a time

Over the last two years the c4c Paediatric Medicine Academy has been hard at work organizing, developing and providing high quality educational and training programs aimed at equipping researchers and clinicians with the best tools and techniques for optimal organisation, implementation and delivery of effective paediatric clinical trials. To-date, c4c has had the honour of…

c4c providing strategic feasibility advice

Experts selected from the conect4children (c4c) Expert Groups are available to provide Strategic Feasibility Advice (scientific advice), to c4c beneficiaries who are developing medicines for children. Advice is available on any aspect of a paediatric clinical study or development program, e.g. trial design, including end points and assessment schedules. Patient and/or parent experts may also…

c4c’s 1st publication

conect4children (c4c) is pleased to announce its first publication.   The review titled “European research networks to facilitate drug research in children” has been published by the British Journal of Clinical Pharmacology.   This review discusses the need for a structured approach to drug development by establishing and utilizing research networks and infrastructures. The publication…

c4c submits a shared response to the FDA consultation

On behalf of European Rare Disease community, c4c submits a shared response to the FDA consultation about a global clinical trials network in rare diseases.   On May 29th this year, the FDA opened a consultation to obtain information and comments from patients, patient advocates, the scientific community, health professionals, other regulatory and health authorities in the…